![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, July 30, 2022 12:29:48 PM
<<<<<< Not sure why there is some much attention being paid here to the SofPulse product >>>>>
2) Trying to lump BIEL, OEM contracts with KT Tape/Scott-DJO/SAI Brands, in with ENDV, who had $73k in Sales for 2021, is ridiculous.
<<<<<< two different products, both FDA authorized, both clinically proven, are unable to find a market >>>>>>
3) Setting arbitrary deadlines for the success/failure of BIEL have not worked out well for the last 15 years.
<<<<<<<<< next 2 quarters are do or die for BIEL >>>>>>>>>>>
4) Quotes posted with no link to the actual Study/Trial, why not provide a link to the Study/Trial so that readers can see the source material?
<<<<<< "See Attached Study" >>>>>>
5) Serious Red Flag , Claims of 300% and 400% reduction in Pain. Pain is generally quantified with numers, a 1-10 scale being most common. If a patient's Pain is reduced from 10 to 5 that is a 50% reduction, from 10 to 1 would be a 90% decrease. There is no 400% decrease on a numerical pain scale.
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM